<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03836066</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 18/03_TELMA</org_study_id>
    <secondary_id>2018-004654-17</secondary_id>
    <nct_id>NCT03836066</nct_id>
  </id_info>
  <brief_title>Atezolizumab Plus Bevacizumab in First Line NSCLC Patients</brief_title>
  <acronym>TELMA</acronym>
  <official_title>A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación GECP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación GECP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase II clinical trial of atezolizumab in combination with&#xD;
      bevacizumab as first line treatment for locally advanced or metastasic high-intermediate&#xD;
      tumour mutation burden selected NSCLC patients. 102 patients will be enrolled in this trial&#xD;
      to examine the efficacy of this combination measured by progression free survival according&#xD;
      to response evaluation Criteria in solid tumours (RECIST) version 1.1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy-naïve patients high-intermediate TMB (TMB≥10 mutations/MB) and with locally&#xD;
      advanced or metastatic non-squamous non-small cell lung cancer patients will be selected.&#xD;
      Enroled patientswill receive 1200 mg of atezolizumab and 15mg/Kg of Avastin® (bevacizumab)&#xD;
      administered by IV infusion every 21 days (+/- 3 days).&#xD;
&#xD;
      The treatment will start within 1-5 days from enrolment. Atezolizumab may continue beyond&#xD;
      disease progression per RECIST v1.1 until loss of clinical benefit, unacceptable toxicity,&#xD;
      patient or physician decision to discontinue , or death. Bevacizumab will be administered&#xD;
      until progression disease, unacceptable toxicity, patient or physician decision to&#xD;
      discontinue or death.&#xD;
&#xD;
      For all patients, tumour response data collection will continue until disease progression,&#xD;
      even if the patient stops study treatment prior to disease progression.&#xD;
&#xD;
      The primary endpoint is to evaluate the efficacy of Atezolizumab in combination with&#xD;
      Bevacizumab as measured by Progression Free Survival according to RECIST Version 1.1.&#xD;
&#xD;
      PFS after enrolment is defined as the time from enrolment to the first occurrence of disease&#xD;
      progression or death from any cause, whichever occurs first.&#xD;
&#xD;
      Patient accrual is expected to be completed within 1.5 years excluding a run-in-period of 46&#xD;
      months. Treatment and follow-up are expected to extend the study duration to a total of 4.5&#xD;
      years. Patients will be followed 1.5 years after the end of treatment independently of the&#xD;
      cause of end of treatment. The study will end once survival follow-up has concluded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Atezolizumab in combination with Bevacizumab</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>To evaluate the efficacy of Atezolizumab in combination with Bevacizumab as measured by Progression Free Survival according to Response Evaluation Criteria in Solid Tumours (RECIST).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: Atezolizumab plus Bevacizumab arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab-Bevacizumab</intervention_name>
    <description>Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg</description>
    <arm_group_label>Experimental: Atezolizumab plus Bevacizumab arm</arm_group_label>
    <other_name>Tecentriq-Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged ≥ 18 years old&#xD;
&#xD;
          2. ECOG performance status of 0 or 1.&#xD;
&#xD;
          3. Histologically or cytologically confirmed, Stage IIIB or IV non-squamous NSCLC&#xD;
             according to 8th version of the International Association for the Study of Lung Cancer&#xD;
             Staging Manual in Thoracic Oncology&#xD;
&#xD;
          4. No prior treatment for Stage IIIB or IV non-squamous NSCLC.&#xD;
&#xD;
          5. Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or&#xD;
             chemo-radiotherapy with curative intent for non-metastatic disease must have&#xD;
             experienced a treatment-free interval of at least 6 months from randomization since&#xD;
             the last chemotherapy, radiotherapy, or chemo-radiotherapy.&#xD;
&#xD;
          6. Patients with a treated asymptomatic CNS metastasis are eligible, provided they meet&#xD;
             all of the following criteria:&#xD;
&#xD;
               1. Only supratentorial and cerebellar metastases allowed (i.e., no metastases to&#xD;
                  midbrain, pons, medulla or spinal cord).&#xD;
&#xD;
               2. No ongoing requirement for corticosteroids as therapy for CNS disease.&#xD;
&#xD;
               3. No stereotactic radiation within 7 days or whole-brain radiation within 14 days&#xD;
                  prior to randomization.&#xD;
&#xD;
               4. No evidence of interim progression between the completion of CNS-directed therapy&#xD;
                  and the screening radiographic study. Patients with new asymptomatic CNS&#xD;
                  metastases detected at the screening scan must receive radiation therapy and/or&#xD;
                  surgery for CNS metastases. Following treatment, these patients may then be&#xD;
                  eligible without the need for an additional brain scan prior to inclusion, if all&#xD;
                  other criteria are met.&#xD;
&#xD;
          7. Patients with high-intermediate Tumour Mutational Burden analysed by Foundation&#xD;
             Medicine (≥10 mutations/ MB) performed by a Foundation Medicine laboratory on&#xD;
             previously obtained archival tumour tissue or tissue obtained from a biopsy at&#xD;
             prescreening (sample must fulfil minimal sample requirements of 20% tumour cellularity&#xD;
             and a minimum surface of 25mm2).&#xD;
&#xD;
          8. Measurable disease, as defined by RECIST v1.1. Previously irradiated lesions can only&#xD;
             be considered as measurable disease if disease progression has been unequivocally&#xD;
             documented at that site since radiation and the previously irradiated lesion is not&#xD;
             the only site of disease.&#xD;
&#xD;
          9. Adequate hematologic and organ function defined by the following laboratory results&#xD;
             obtained within 14 days prior to randomization:&#xD;
&#xD;
             Neutrophils ≥ 1500 cells/μL without granulocyte colony-stimulating factor support.&#xD;
&#xD;
               -  Lymphocyte count ≥ 500/μL.&#xD;
&#xD;
               -  Platelet count ≥ 100,000/μL without transfusion.&#xD;
&#xD;
               -  Haemoglobin ≥ 9.0 g/dL. Patients may be transfused to meet this criterion.&#xD;
&#xD;
               -  INR or aPTT ≤ 1.5 × upper limit of normal (ULN). This applies only to patients&#xD;
                  who are not receiving therapeutic anticoagulation; patients receiving therapeutic&#xD;
                  anticoagulation should be on a stable dose.&#xD;
&#xD;
               -  AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN, with the following exceptions:&#xD;
                  Patients with documented liver metastases: AST and/or ALT ≤ 5 × ULN. Patients&#xD;
                  with documented liver or bone metastases: alkaline phosphatase ≤ 5 × ULN.&#xD;
&#xD;
               -  Serum bilirubin ≤ 1.25 × ULN. Patients with known Gilbert disease who have serum&#xD;
                  bilirubin level ≤ 3 × ULN may be enrolled.&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 × ULN or creatinine clearance of ≥45ml/min (based on the&#xD;
                  Cockcroft Gault formula).&#xD;
&#xD;
         10. All patients are notified of the investigational nature of this study and signed a&#xD;
             written informed consent in accordance with institutional and national guidelines,&#xD;
             including the Declaration of Helsinki prior to any trial-related intervention.&#xD;
&#xD;
         11. For female patients of childbearing potential, agreement (by patient and/or partner)&#xD;
             to use a highly effective form(s) of contraception that results in a low failure rate&#xD;
             (&lt; 1% per year) when used consistently and correctly, and to continue its use for 5&#xD;
             months after the last dose of Atezolizumab and/or 6 months after the last dose of&#xD;
             Bevacizumab, whichever is later. Such methods include: combined (oestrogen and&#xD;
             progestogen containing) hormonal contraception, progestogen-only hormonal&#xD;
             contraception associated with inhibition of ovulation together with another additional&#xD;
             barrier method always containing a spermicide, intrauterine device (IUD): intrauterine&#xD;
             hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on&#xD;
             the understanding that this is the only one partner during the whole study duration),&#xD;
             and sexual abstinence.&#xD;
&#xD;
         12. For male patients with female partners of childbearing potential, agreement (by&#xD;
             patient and/or partner) to use a highly effective form(s) of contraception that&#xD;
             results in a low failure rate [&lt; 1% per year] when used consistently and correctly,&#xD;
             and to continue its use for 6 months after the last dose of Bevacizumab. Male patients&#xD;
             should not donate sperm during this study and for at least 6 months after the last&#xD;
             dose of Bevacizumab.&#xD;
&#xD;
         13. Oral contraception should always be combined with an additional contraceptive method&#xD;
             because of a potential interaction with the study drugs. The same rules are valid for&#xD;
             male patients involved in this clinical study if they have a partner of childbirth&#xD;
             potential. Male patients must always use a condom.&#xD;
&#xD;
         14. Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or&#xD;
             surgically sterile must have a negative serum pregnancy test result within 14 days&#xD;
             prior to initiation of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a sensitizing mutation in the epidermal growth factor receptor (EGFR)&#xD;
             gene.&#xD;
&#xD;
          2. Patients with an anaplastic lymphoma kinase (ALK) fusion oncogene.&#xD;
&#xD;
          3. Patients with an STK-1 Ligand alteration.&#xD;
&#xD;
          4. Patients with MDM2 amplification.&#xD;
&#xD;
          5. Patients with ROS1 translocations.&#xD;
&#xD;
          6. Active or untreated CNS metastases as determined by CT or magnetic resonance imaging&#xD;
             (MRI) evaluation during screening and prior radiographic assessments.&#xD;
&#xD;
          7. Spinal cord compression not definitively treated with surgery and/or radiation or&#xD;
             previously diagnosed and treated spinal cord compression without evidence that disease&#xD;
             has been clinically stable for &gt; 2 weeks prior to randomization.&#xD;
&#xD;
          8. Leptomeningeal disease.&#xD;
&#xD;
          9. Uncontrolled tumour-related pain. Patients requiring pain medication must be on a&#xD;
             stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy&#xD;
             (e.g., bone metastases or metastases causing nerve impingement) should be treated&#xD;
             prior to initiation of study drug. Patients should be recovered from the effects of&#xD;
             radiation. There is no required minimum recovery period. Asymptomatic metastatic&#xD;
             lesions whose further growth would likely cause functional deficits or intractable&#xD;
             pain (e.g., epidural metastasis that is not currently associated with spinal cord&#xD;
             compression) should be considered for locoregional therapy, if appropriate, prior to&#xD;
             initiation of study drug.&#xD;
&#xD;
         10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently). Patients with indwelling&#xD;
             catheters (e.g., PleurX®) are allowed.&#xD;
&#xD;
         11. Uncontrolled or symptomatic hypercalcemia (&gt; 1.5 mmol/L ionized calcium or Ca &gt; 12&#xD;
             mg/dL or corrected serum calcium &gt; ULN).&#xD;
&#xD;
         12. Malignancies other than NSCLC within 5 years prior to randomization, with the&#xD;
             exception of those with a negligible risk of metastasis or death (e.g., expected&#xD;
             5-year OS &gt; 90%) treated with expected curative outcome (such as adequately treated&#xD;
             carcinoma in situ of the cervix, basal or squamous-cell skin cancer, localized&#xD;
             prostate cancer treated surgically with curative intent, ductal carcinoma in situ&#xD;
             treated surgically with curative intent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Mallorca</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Llàtzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Mallorca</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castelló</name>
      <address>
        <city>Castelló</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politécnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Web page of the sponsor where users can find more information about Fundación GECP studies</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC, Atezolizumab, Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03836066
org study id: GECP 18/03_TELMA
secondary id: 2018-004654-17
nct id: NCT03836066
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This is a multi-center phase II clinical trial of atezolizumab in combination with
      bevacizumab as first line treatment for locally advanced or metastasic high-intermediate
      tumour mutation burden selected NSCLC patients. 102 patients will be enrolled in this trial
      to examine the efficacy of this combination measured by progression free survival according
      to response evaluation Criteria in solid tumours (RECIST) version 1.1.
Chemotherapy-naïve patients high-intermediate TMB (TMB≥10 mutations/MB) and with locally
      advanced or metastatic non-squamous non-small cell lung cancer patients will be selected.
      Enroled patientswill receive 1200 mg of atezolizumab and 15mg/Kg of Avastin® (bevacizumab)
      administered by IV infusion every 21 days (+/- 3 days).

      The treatment will start within 1-5 days from enrolment. Atezolizumab may continue beyond
      disease progression per RECIST v1.1 until loss of clinical benefit, unacceptable toxicity,
      patient or physician decision to discontinue , or death. Bevacizumab will be administered
      until progression disease, unacceptable toxicity, patient or physician decision to
      discontinue or death.

      For all patients, tumour response data collection will continue until disease progression,
      even if the patient stops study treatment prior to disease progression.

      The primary endpoint is to evaluate the efficacy of Atezolizumab in combination with
      Bevacizumab as measured by Progression Free Survival according to RECIST Version 1.1.

      PFS after enrolment is defined as the time from enrolment to the first occurrence of disease
      progression or death from any cause, whichever occurs first.

      Patient accrual is expected to be completed within 1.5 years excluding a run-in-period of 46
      months. Treatment and follow-up are expected to extend the study duration to a total of 4.5
      years. Patients will be followed 1.5 years after the end of treatment independently of the
      cause of end of treatment. The study will end once survival follow-up has concluded.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Efficacy of Atezolizumab in combination with Bevacizumab
time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
description: To evaluate the efficacy of Atezolizumab in combination with Bevacizumab as measured by Progression Free Survival according to Response Evaluation Criteria in Solid Tumours (RECIST).
arm group label: Experimental: Atezolizumab plus Bevacizumab arm
arm group type: Experimental
description: 1 group, Atezolizumab 1200mb + Bevacizumab 15 mg/kg (IV),every 21 days.
intervention type: Drug
intervention name: Atezolizumab-Bevacizumab
description: Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
arm group label: Experimental: Atezolizumab plus Bevacizumab arm
other name: Tecentriq-Avastin
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Mariano Provencio, MD
role: Principal Investigator
affiliation: Hospital Universitario Puerta de Hierro
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Spain
url: http://www.gecp.org
description: Web page of the sponsor where users can find more information about Fundación GECP studies
responsible party type: Sponsor
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Bevacizumab
mesh term: Atezolizumab
sharing ipd: No